Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

gain over time. To date, the only highly effective treatment option is surgical and limited to the minority of patients who have advanced to the most severe forms of obesity," said Steven R. Smith, M.D., professor and assistant director of clinical research at the Pennington Biomedical Research Center. "Providing the over 80 million overweight and obese Americans who have a BMI less than 35 kg/m2 with safe treatment options that offer compelling weight loss would be a significant advancement in obesity drug development."

The combination therapy was well tolerated, and no cardiovascular or neuropsychiatric (such as anxiety or depression) safety signals were observed. Consistent with previous clinical experience, the most common side effects seen with pramlintide/metreleptin combination treatment were injection site adverse events and nausea, which were mostly mild or moderate and transient in nature.

"These findings provide us with valuable data that will inform our clinical and product development strategy moving forward," said Christian Weyer, M.D., vice president, corporate development, diabetes and obesity at Amylin Pharmaceuticals. "Our integrated neurohormonal approach to obesity provides a broad research and development platform that has the potential to yield transformational therapies that address a range of unmet patient needs across the various classes of obesity."

Study Details

This Phase 2, 28-week, double-blind, placebo-controlled multi-center study randomized 608 obese or overweight patients with a BMI ranging from 27-45 kg/m2. Patients were well-distributed across this BMI range, with approximately 40% of patients at a starting BMI less than 35 kg/m2. Following a one-week placebo lead-in period, study subjects were randomized in a balanced fashion to receive twice-daily therapy with one of the following eight treatment regimens: 1) placebo/placebo; 2) pramlintide 360 mcg/placebo; 3)
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, with ... announce an Open House at their Swedesboro location, 95 Woodstown ... from 10 AM to 2 PM. , During the ... will be on hand to talk to people about the ... complimentary cosmetic consultations. There will also be specials offered, such ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Bed bug cases ... protect themselves from the looming higher risk of becoming the ... a new bed bug guideline. In the guide, the company ... and avoiding them while traveling. , According to ... an increase of bed bug infestation during summer: the warm ...
(Date:5/24/2013)... , May 24, 2013 Senomyx ... using proprietary taste science technologies to discover, develop, and ... David Linemeyer , Ph.D., the Company,s Vice President, ... President, Investor Relations & Corporate Communications, will present an ... 31, at 10:25 a.m. Eastern Time (7:25 a.m. Pacific ...
(Date:5/24/2013)... Many factors impact tissues targeting such as protein ... the blood-tissue barrier. Even when tissue disposition is achieved, ... tissue rather than the total tissue concentration. , A ... guide lead optimization, predict in vivo activity in animal ... impact the likely human clinical dose. , In this ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... Intellect Neurosciences, Inc. ( OTC Bulletin Board : ILNS ... for the treatment and prevention of Alzheimer,s disease released today the ... CEO. , , Dear Shareholders, ... to serve as Chairman and CEO of Intellect Neurosciences Inc., which ...
... is $45.8 billion, 180,007 jobs , , ... Carolina has invested more than $1 billion in its expanding ... economic impact exceeds $45 billion, according to data released today ... , Norris Tolson, president and CEO of the ...
... MADISON, N.J., Nov. 20 At a meeting of the ... today, a dividend of fifty cents($0.50) per share on the ... 2009 to stockholders of record at the close of business,on ... Wyeth is one of the world,s largest research-driven pharmaceutical and,health ...
Cached Biology Technology:Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 2Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 3Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 4Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 5North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 2North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 3North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 4North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 5
(Date:5/24/2013)... the immune system to combat metastatic cancer , ... destruction by the immune system. Stimulation of the immune ... are many factors that cause the immune system to ... that function to suppress the immune system response. In ... , researchers led by Ronald Levy at Stanford University ...
(Date:5/24/2013)... from around the world today issued a stark warning ... one or two generations, the majority of the 9 ... handicap of severe pressure on fresh water, an absolutely ... This handicap will be self-inflicted and is, we believe, ... underlying problems led by mismanagement and sent a prescription ...
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... has been brought back to life in stunning 3D ... In a paper published in the latest issue of ... Ghent University in Belgium report on the use of ... (VHR-CT) to digitally dissect tiny fossils and reveal the ...
... Gene therapy administered intravenously could be an effective agent ... of ionizing radiation in the event of large-scale exposure ... animal study presented today by University of Pittsburgh researchers ... for Therapeutic Radiology and Oncology (ASTRO) in Los Angeles. ...
... Oct. 26, 2007 From defusing bombs to treating post ... The University of Houston will host a Department of ... and 2 at the Hilton UH Hotel and Conference Center. ... give attendees an opportunity to connect with DoD services and ...
Cached Biology News:Scientist brings 50 million year old spider 'back to life' 2Intravenous gene therapy protects normal tissue of mice during whole-body radiation 2US Army, US Navy, US Air Force, US Marines, US Department of Defense conference held at UH 2US Army, US Navy, US Air Force, US Marines, US Department of Defense conference held at UH 3
...
... Quansys Biosciences Q-Plex Array is a new ... human, mouse, and rat research. The Q-Plex ... ELISA-based test where 4 distinct capture antibodies ... a 96-well plate in a defined array. ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Pro260 reagents and supplies, for 10 ... sufficient to perform protein analysis with ... electrophoresis system. Supplied are 3 x ... Pro260 stain, 60 microliters Pro260 ladder ...
Biology Products: